<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03525405</url>
  </required_header>
  <id_info>
    <org_study_id>BBI608-104</org_study_id>
    <nct_id>NCT03525405</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Mass Balance of 14C-Napabucasin in Healthy Adult Male Subjects</brief_title>
  <official_title>A Phase I, Open Label, Single Dose Study to Evaluate the Mass Balance of 14C-Napabucasin in Healthy Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sumitomo Dainippon Pharma Oncology, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sumitomo Dainippon Pharma Oncology, Inc</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, single-center, open-label, single-sequence, study evaluating the&#xD;
      absorption, metabolism, and excretion of napabucasin in healthy adult male volunteers using a&#xD;
      mixture 14C-radiolabeled and unlabeled material.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 18, 2018</start_date>
  <completion_date type="Actual">June 2, 2018</completion_date>
  <primary_completion_date type="Actual">June 2, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics for napabucasin and metabolites by assessing plasma concentration</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics for napabucasin and metabolites by assessing urinary concentration</measure>
    <time_frame>Up to 12 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics for napabucasin and metabolites by assessing fecal concentration</measure>
    <time_frame>Up to 12 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with Adverse Events</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>ADME</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Single Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>napabucasin</intervention_name>
    <description>Single 240 mg dose containing 100 Î¼Ci of 14C-napabucasin will be administered with 240 mL of water following an overnight fast.</description>
    <arm_group_label>Single Dose</arm_group_label>
    <other_name>BBI-608</other_name>
    <other_name>BBI608</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
        1. An Institutional Review Board (IRB) approved informed consent is signed and dated prior&#xD;
        to any study-related activities.&#xD;
&#xD;
        2. Subject is male. 3. Subject is between the ages of 18 and 45 years, inclusive at&#xD;
        screening. 4. Subject has a body mass index between 18 and 34 kg/m^2 (weight/[height]^2)&#xD;
        inclusive at screening.&#xD;
&#xD;
        5. Subject has normal (or abnormal and clinically insignificant according to the&#xD;
        Investigator) laboratory values at screening. 6. Subject is in good health, determined by&#xD;
        no clinically significant findings from medical history, physical examination, 12-lead&#xD;
        electrocardiogram (ECG), vital signs measurements, or clinical laboratory evaluations at&#xD;
        Screening or Check-in Day -1 as assessed by the Investigator (or designee). Subject has the&#xD;
        ability to understand the requirements of the study and a willingness to comply with all&#xD;
        study procedures.&#xD;
&#xD;
        7. Subject has not consumed and agrees to abstain from taking any dietary supplements,&#xD;
        herbal products, and non-prescription drugs (except as authorized by the Investigator and&#xD;
        Medical Monitor) for 14 days prior to clinical research unit (CRU) admission through&#xD;
        follow-up call.&#xD;
&#xD;
        8. Subject has not consumed and agrees to abstain from taking any prescription drugs&#xD;
        (except as authorized by the Investigator and Medical Monitor) during the 14 days prior to&#xD;
        CRU admission through follow-up call.&#xD;
&#xD;
        9. Subject has not consumed alcohol-containing beverages for 3 days prior to CRU admission&#xD;
        and agrees not to consume alcohol through clinic discharge. 10. Subject has not consumed&#xD;
        char-broiled meats, cruciferous vegetables, and grapefruit-, apple-, or Seville&#xD;
        orange-containing products within the 3 days prior to CRU admission and agrees not to&#xD;
        consume Seville oranges, grapefruit and grapefruit juice through clinic discharge.&#xD;
&#xD;
        11. Subject has not used tobacco- and nicotine-containing products within 2 months prior to&#xD;
        the CRU admission and agrees to abstain from using tobacco- and nicotine-containing&#xD;
        products through clinic discharge.&#xD;
&#xD;
        12. Subject agrees to abstain from consuming caffeine- or xanthine-containing products from&#xD;
        3 days prior to CRU admission through clinic discharge.&#xD;
&#xD;
        13. History of a minimum of 1 bowel movement per day Exclusion criteria&#xD;
&#xD;
          1. Subject has a history of illicit drug abuse in the past year or displays current&#xD;
             evidence of such abuse in the opinion of the Investigator.&#xD;
&#xD;
          2. Subject has positive findings on urine drug screen (including cotinine).&#xD;
&#xD;
          3. Subject is positive for human immunodeficiency virus (HIV), hepatitis B and/or&#xD;
             hepatitis C on Screening assessments.&#xD;
&#xD;
          4. Subject has a QTcF &gt;450 msec at screening (confirmed by repeat).&#xD;
&#xD;
          5. Subject has a female partner who is either pregnant, nursing, or planning to become&#xD;
             pregnant during the study or within 90 days after the last dose of the study drug, or&#xD;
             unwilling to follow the contraception requirements.&#xD;
&#xD;
          6. Subject has a clinically significant acute illness within 1 week of CRU admission, or&#xD;
             symptoms of active illness at check-in, at discretion of the Investigator (or&#xD;
             designee).&#xD;
&#xD;
          7. Subject has a hypersensitivity or allergy to napabucasin or the ingredients of&#xD;
             napabucasin, or other clinically significant allergies in the opinion of the&#xD;
             Investigator.&#xD;
&#xD;
          8. Subject has donated plasma within 7 days of drug administration.&#xD;
&#xD;
          9. Subject has donated 1 or more pints of blood (or equivalent blood loss) within 30 days&#xD;
             prior to drug administration.&#xD;
&#xD;
         10. Subject has a history of chronic Gastroesophageal reflux disease (GERD) or has used&#xD;
             omeprazole or other proton pump inhibitors within 3 months of Screening.&#xD;
&#xD;
         11. Subject has congenital non-hemolytic hyperbilirubinemia [e.g., Gilbert's syndrome].&#xD;
&#xD;
         12. Subject has any condition possibly affecting drug absorption (e.g., gastrectomy,&#xD;
             cholecystectomy, or other gastrointestinal tract surgery, except appendectomy).&#xD;
&#xD;
         13. Subject has participated in an investigational drug study within 30 days or 5&#xD;
             half-lives (whichever is longer) of exposure to another investigational medication&#xD;
             prior to CRU admission.&#xD;
&#xD;
         14. Subject is an employee of the Investigator or study center, with direct involvement in&#xD;
             the proposed study or other studies under the direction of that Investigator or study&#xD;
             center, or a family member of the employees or the Investigator.&#xD;
&#xD;
         15. Subjects with exposure to significant diagnostic or therapeutic radiation (e.g.,&#xD;
             serial Xray, computed tomography scan, barium meal) or employment in a job requiring&#xD;
             radiation exposure monitoring within 12 months prior to check-in.&#xD;
&#xD;
         16. Subjects who have participated in a radiolabeled drug study where exposures are known&#xD;
             to the Investigator within the previous 4 months prior to admission to the clinic for&#xD;
             this study or participated in a radiolabeled drug study where exposures are not known&#xD;
             to the Investigator within the previous 6 months prior to admission to the clinic for&#xD;
             this study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Covance Clinical Research Unit</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 30, 2018</study_first_submitted>
  <study_first_submitted_qc>May 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2018</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

